| Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome V Pengo, G Denas, G Zoppellaro, SP Jose, A Hoxha, A Ruffatti, L Andreoli, ... Blood, The Journal of the American Society of Hematology 132 (13), 1365-1371, 2018 | 725 | 2018 |
| Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome V Pengo, A Ruffatti, C Legnani, P Gresele, D Barcellona, N Erba, S Testa, ... Journal of thrombosis and haemostasis 8 (2), 237-242, 2010 | 705 | 2010 |
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study V Pengo, A Ruffatti, C Legnani, S Testa, T Fierro, F Marongiu, ... Blood, The Journal of the American Society of Hematology 118 (17), 4714-4718, 2011 | 490 | 2011 |
| Standardized Low–Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery: An Inception Cohort Management Study V Pengo, U Cucchini, G Denas, N Erba, G Guazzaloca, L La Rosa, ... Circulation 119 (22), 2920-2927, 2009 | 214* | 2009 |
| Antiphospholipid syndrome: antibodies to domain 1 of β2‐glycoprotein 1 correctly classify patients at risk V Pengo, A Ruffatti, M Tonello, S Cuffaro, A Banzato, E Bison, G Denas, ... Journal of thrombosis and haemostasis 13 (5), 782-787, 2015 | 128 | 2015 |
| Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile V Pengo, A Ruffatti, T Del Ross, M Tonello, S Cuffaro, A Hoxha, A Banzato, ... Journal of thrombosis and haemostasis 11 (8), 1527-1531, 2013 | 116 | 2013 |
| Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs G Patti, I Cavallari, F Andreotti, P Calabro, P Cirillo, G Denas, M Galli, ... Nature Reviews Cardiology 16 (2), 113-130, 2019 | 95 | 2019 |
| Antiphospholipid syndrome and the heart: a case series and literature review G Denas, SP Jose, A Bracco, G Zoppellaro, V Pengo Autoimmunity reviews 14 (3), 214-222, 2015 | 91 | 2015 |
| Antibodies to Domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS) A Banzato, N Pozzi, R Frasson, V De Filippis, A Ruffatti, E Bison, ... Thrombosis research 128 (6), 583-586, 2011 | 88 | 2011 |
| Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant V Pengo, S Testa, I Martinelli, A Ghirarduzzi, C Legnani, P Gresele, ... Thrombosis research 135 (1), 46-49, 2015 | 81 | 2015 |
| Correct laboratory approach to APS diagnosis and monitoring V Pengo, A Banzato, G Denas, SP Jose, E Bison, A Hoxha, A Ruffatti Autoimmunity reviews 12 (8), 832-834, 2013 | 81 | 2013 |
| Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid … V Pengo, A Banzato, E Bison, G Zoppellaro, S Padayattil Jose, G Denas Lupus 25 (3), 301-306, 2016 | 79 | 2016 |
| What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? V Pengo, A Banzato, E Bison, A Bracco, G Denas, A Ruffatti Seminars in thrombosis and hemostasis 38 (04), 322-327, 2012 | 74 | 2012 |
| Long-term use of vitamin K antagonists and incidence of cancer: a population-based study V Pengo, F Noventa, G Denas, MF Pengo, U Gallo, AM Grion, S Iliceto, ... Blood, The Journal of the American Society of Hematology 117 (5), 1707-1709, 2011 | 62 | 2011 |
| Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases G Denas, F Marzot, P Offelli, A Stendardo, U Cucchini, R Russo, G Nante, ... Journal of thrombosis and thrombolysis 27, 340-347, 2009 | 60 | 2009 |
| Trial of rivaroxaban in antiPhospholipid syndrome (TRAPS): two‐year outcomes after the study closure V Pengo, A Hoxha, L Andreoli, A Tincani, E Silvestri, D Prisco, T Fierro, ... Journal of thrombosis and haemostasis 19 (2), 531-535, 2021 | 59 | 2021 |
| Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti‐phosphatidyl‐serine/prothrombin antibodies to lupus anticoagulant activity MG Cattini, E Bison, E Pontara, C Cheng, G Denas, V Pengo Journal of Thrombosis and Haemostasis 18 (5), 1124-1132, 2020 | 59 | 2020 |
| Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns V Pengo, T Del Ross, A Ruffatti, E Bison, MG Cattini, E Pontara, S Testa, ... Thrombosis research 172, 172-178, 2018 | 59 | 2018 |
| Current and emerging direct oral anticoagulants: state-of-the-art G Lippi, R Gosselin, EJ Favaloro Seminars in thrombosis and hemostasis 45 (05), 490-501, 2019 | 58 | 2019 |
| Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study D Poli, E Antonucci, V Pengo, L Migliaccio, S Testa, C Lodigiani, N Coffetti, ... International journal of cardiology 267, 68-73, 2018 | 54 | 2018 |
